Business Daily Media

Business Marketing

.

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

  • Written by ACN Newswire - Press Releases

image

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

Thi

Read more //?#

Popular

Engaging staff during COVID19 a winning formula for Arriba Group

Leading corporate health provider Arriba Group has ranked #1 in the AFR BOSS Best Places to Work 2022 in the Health Category, being recognised for their efforts to support employees during COVID19. Arriba Group launched their...

New leaders at Reflections Holiday Parks

Newcastle leaders reunite to achieve bold new vision at Reflections Holiday Parks Reflections Holiday Parks has appointed top Newcastle talent Lauren Eyles and Peter Chapman to its experienced Leadership Team to help achieve a ...

Need to ask your boss for menopause leave? Here are 5 tips directly from an expert

The stage of life called menopause is when a woman’s reproductive hormone production begins to change, marking a significant new milestone in our lives. The beginning of menopause, otherwise known as perimenopause, typically o...

Virtual Office
Tomorrow Business Growth